Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 19/20 | 0.65 |
| ▸ | MMP1 | P03956 | 18/20 | 0.65 |
| ▸ | MMP9 | P14780 | 13/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940219 | 0.87 | MMP13 (0.85) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6609075 | 0.82 | MMP13 (0.77) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6609170 | 0.82 | MMP1 (0.82) | MMP13ADAM17MMP1MMP9POLB | |
| SCHEMBL3944053 | 0.81 | MMP13 (0.76) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3950441 | 0.81 | MMP13 (0.73) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3939462 | 0.81 | MMP13 (0.73) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3947778 | 0.80 | MMP13 (0.85) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6612352 | 0.79 | MMP13 (0.84) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL6608973 | 0.79 | MMP1 (0.64) | MMP13ADAM17MMP1MMP9 | |
| SCHEMBL3948361 | 0.79 | MMP13 (0.72) | MMP13ADAM17MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| EP-1147095-A1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044730-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]BENZODIAZEPINE-3-HYDROXAMIC ACID AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |